Clarithromycin pulsatile - MiddleBrook
Alternative Names: Clarithromycin PULSYS™; Pulsatile clarithromycin; PULSYS™ clarithromycinLatest Information Update: 29 Dec 2021
Price :
$50 *
At a glance
- Originator Advancis Pharmaceutical
- Developer MiddleBrook Pharmaceuticals
- Class Antibacterials; Macrolides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 26 Aug 2009 No development reported - Phase-I/II for Bacterial infections in USA (PO)
- 28 Jun 2007 Advancis Pharmaceutical is now called MiddleBrook Pharmaceuticals
- 20 Aug 2004 Phase-I/II clinical trials in Bacterial infections in USA (PO)